Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Disappointment For Novartis As England’s NICE Says No To Migraine Drug Again

Doubts linger over Aimovig's cost effectiveness

Executive Summary

New cost-effectiveness analyses and an improved deal for Aimovig have failed to change the health technology assessment body's mind about routine funding for the migraine prevention drug.

You may also be interested in...



UK Funding Nod For Novartis Migraine Drug After Bumpy Ride

Following two previous rejections by the UK’s health technology assessment body and an appeal, Aimovig is now available on the National Health Service for preventing migraine.

Scottish HTA Body OKs Novartis’ Aimovig For Migraine And Eisai’s Lenvima For Cancer

Scotland’s health technology appraisal body has OKd Novartis’s Aimovig for migraines. England’s NICE has postponed a meeting on the drug after a large number of comments were received following the institute’s initial knockback.

Valneva Wins EU Nod For COVID-19 Vaccine

In contrast with the five COVID-19 vaccines that are approved in the EU under conditional marketing authorizations, the European Medicines Agency has recommended that Valneva’s vaccine receive a standard approval.

Topics

Latest News
UsernamePublicRestriction

Register

PS140926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel